How Paclitaxel Binds to Albumin
Paclitaxel, a taxane chemotherapy drug, has low aqueous solubility and binds extensively to plasma proteins, primarily albumin (about 89-98% bound). This binding occurs mainly through hydrophobic interactions with albumins Sudlow sites I and II on the protein's surface, stabilizing the drug in circulation.[1][2]
Impact on Plasma Distribution and Half-Life
Albumin binding reduces paclitaxel's free fraction (only 5-11% unbound), slowing its distribution to tissues. This extends the plasma half-life from short unbound durations to 5-30 hours (depending on dose/formulation), allowing sustained exposure. Without binding, rapid clearance would limit efficacy.[1][3]
Changes in Tissue Penetration
Bound paclitaxel cannot easily cross capillary endothelium, concentrating it in the vascular compartment. Free drug penetrates tumors via leaky vasculature (enhanced permeability and retention effect), improving intratumoral delivery compared to unbound forms that distribute too quickly.[2][4]
Effects on Metabolism and Clearance
Binding shields paclitaxel from hepatic CYP2C8 and CYP3A4 metabolism and biliary excretion. This decreases clearance rate (typically 10-20 mL/min/m²) versus unbound analogs, prolonging systemic availability. Competition with other albumin-bound drugs (e.g., diazepam) can transiently increase free fraction and toxicity.[1][3]
Clinical Formulation: Albumin-Bound Paclitaxel (Abraxane)
Abraxane uses albumin nanoparticles (nab-paclitaxel) for cremophor-free delivery. Paclitaxel binds reversibly to these particles in plasma, mimicking endogenous albumin transport. This boosts solubility, raises free drug at tumor sites via gp60 receptor-mediated transcytosis and caveolin-1 uptake, and cuts infusion reactions—pharmacokinetics show 30-50% higher AUC and faster clearance (half-life ~27 hours) than cremophor-paclitaxel.[4][5]
Sources
[1]: DrugBank: Paclitaxel Pharmacokinetics
[2]: PubMed: Paclitaxel-Albumin Binding
[3]: FDA Label: Taxol
[4]: FDA Label: Abraxane
[5]: Clinical Pharmacology: nab-Paclitaxel